Welcome to our dedicated page for Retractable Technologies news (Ticker: RVP), a resource for investors and traders seeking the latest updates and insights on Retractable Technologies stock.
Retractable Technologies, Inc. reports developments tied to its safety medical products business, including VanishPoint® syringes, blood collection and IV catheter products, Patient Safe® syringes, and EasyPoint® retractable needles. The company manufactures and markets devices designed to reduce needlestick injuries, product reuse, and catheter-related contamination risks, with distribution through specialty and general line medical distributors.
Recurring news themes for RVP include operating results, domestic and international sales trends, product mix shifts involving EasyPoint® needles, tariff exposure on products imported from China, and changes in manufacturing activity as the company expands domestic production where practical. Updates also cover workforce reductions, product designations, and dividends on Series II and Series III Class B Convertible Preferred Stock.
Retractable Technologies (RVP) announced support for Senator Marsha Blackburn’s ONSHORE Manufacturing Act, which is designed to boost domestic production of critical medical supplies through tax incentives for U.S. manufacturers. The company, which has produced medical devices in Little Elm, Texas for decades, highlights that the proposed legislation would encourage investments in advanced manufacturing equipment and facility modernization. Retractable states it will continue working with policymakers on initiatives that strengthen American manufacturing and improve the resilience of the U.S. medical supply chain.
Retractable Technologies (NYSE American: RVP) reported second quarter 2026 net sales of $7.2 million, down from $10.4 million a year earlier, with an unchanged operating loss of $5.1 million. First‑half 2026 net sales were $14.4 million versus $18.7 million in 2025, and operating losses widened to $11.3 million from $9.8 million.
Net income was $2.8 million for Q2 2026 and a net loss of $1.4 million for the first six months, reflecting a $6.4 million realized gain on sale of equity securities. Overall unit sales fell sharply, mainly from lower EasyPoint® needle demand and timing of flu‑season and customer orders. Domestic production increased to 42.4% of units in the first half (from 38%), tariff expenses declined to $46 thousand in Q2 and $58 thousand year‑to‑date, and operating expenses were flat in Q2 but rose 10.0% for the six‑month period, largely due to donation expense.
Retractable Technologies (NYSE American:RVP) declared quarterly dividends for its Series II and Series III Class B Convertible Preferred Stock. Amounts are $39,050.00 and $18,561.25, covering April 1–June 30, 2026, accruing at $1.00 per share per year.
Dividends will be paid on July 20, 2026 to shareholders of record on July 10, 2026.
Retractable Technologies (NYSE American:RVP) reported Q1 2026 net sales of $7.2 million and an operating loss of $6.2 million, versus $8.3 million and a $4.7 million loss a year earlier.
Unit sales grew 3.6%, tariffs dropped to about $11.6 thousand, operating expenses rose 14%, net loss was $4.2 million, and a 16% April workforce reduction is expected to save $2.2 million annually.
Retractable Technologies (NYSE: RVP) said it reduced its workforce by approximately 16% on April 9, 2026, targeting about $2.2 million in annual wage and benefit savings, equal to roughly 13% of total workforce costs.
One-time separation payments are estimated at $122,000. About 58% of reductions affect manufacturing and manufacturing support while the company shifts production domestically to mitigate tariff costs on imports from China, but it remains reliant on some Chinese-sourced products.
Retractable Technologies (NYSE American: RVP) reported 2025 results for year ended December 31, 2025. Revenue rose 15.8% to $38.3 million, driven by domestic VanishPoint® and EasyPoint® sales and a 64.0% jump in international revenue.
The company recorded a $21.2 million loss from operations and total operating expenses of $21.2 million. Cash decreased $1.6 million to $2.6 million at year-end, and the company held $34.4 million in debt and equity securities. Tariff expense totaled $1.8 million; 62.6% of product sourcing was from China and prevailing tariffs were 120% as of March 9, 2026. Management expects tariffs will materially affect operations.
Retractable Technologies (NYSE American: RVP) declared dividends to holders of its Series II Class B and Series III Class B convertible preferred stock totaling $39,050.00 and $18,561.25, respectively.
Dividends accrue at $1.00 per share per annum, cover Jan 1, 2026–Mar 31, 2026, will be paid on April 20, 2026, to holders of record as of April 10, 2026. Retractable manufactures VanishPoint®, Patient Safe®, and EasyPoint® safety medical products.
Retractable Technologies (NYSE American: RVP) declared cash dividends to holders of its Series II Class B and Series III Class B convertible preferred stock totaling $39,050.00 and $18,561.25, respectively.
Dividends accrued at $1.00 per share per annum for the period October 1, 2025 through December 31, 2025. Payment is scheduled for January 20, 2026 to shareholders of record as of the close of business on January 10, 2026.
Retractable manufactures safety medical products including VanishPoint, Patient Safe, and EasyPoint and distributes them through specialty and general line distributors.
Retractable Technologies (NYSE: RVP) reported Q3 2025 net sales of $10.1M and an operating loss of $3.7M, versus $10.3M sales and a $5.1M operating loss in Q3 2024. For the nine months ended September 30, 2025, net sales were $28.8M and operating losses were $13.5M, compared with $24.0M revenue and $13.9M operating loss in 2024.
Tariffs materially affected results: a 130% tariff on needles and syringes from China and 30% on other Chinese imports; tariffs totaled $2.3M in the first nine months of 2025. The company shifted production to the U.S. (38.3% of products U.S.-made in YTD 2025 vs 10% in 2024) and took workforce reductions.
Q3 net income was $0.37M including $2.4M unrealized investment gains; YTD net loss was $10.2M including $3.2M unrealized losses and a $1.9M litigation settlement.
Retractable Technologies (NYSE: RVP) announced its EasyPoint® Blood Collection Tube Holder with Needle received an Innovative Technology designation from Vizient on November 14, 2025. Vizient's client-led councils designate previously contracted products that may enhance clinical care, patient safety, worker safety, or healthcare operations.
The EasyPoint BCTH uses automated in-vein retraction, a pre-attached needle, an integrated low-profile safety mechanism, and one-handed activation to reduce needlestick exposure, streamline workflow, and render the device non-reusable once activated.